A perspective on anti-CCN2 therapy for chronic kidney disease

Nephrology Dialysis Transplantation

Volumn 29, Issue SUPPL. 1, 2014, Pages

  Falke, Lucas L ^a   Goldschmeding, Roel ^a   Nguyen, Tri Quang ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

CCN2; CKD; fibrosis; intervention; kidney

Indexed keywords

CCN2; CKD; FIBROSIS; INTERVENTION; KIDNEY;

ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; FIBROSIS; HUMANS; RENAL INSUFFICIENCY, CHRONIC;

CELL SURFACE RECEPTOR; CONNECTIVE TISSUE GROWTH FACTOR; CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY; FG 3019;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE MODEL; DRUG EFFICACY; DRUG SAFETY; GENE DELETION; HEART FAILURE; HEART MUSCLE FIBROSIS; HUMAN; KIDNEY FIBROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION;

EID: 84893826488     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft430     Document Type: Review

References (73)

1. Grgic I, Duffield JS, Humphreys BD. The origin of interstitial myofibroblasts in chronic kidney disease. Pediatr Nephrol 2012; 27: 183-193
2. LeBleu VS, Taduri G, O'Connell J et al. Origin and function of myofibroblasts in kidney fibrosis. Nat Med 2013; 19: 1047-1053
3. Eddy AA. The origin of scar-forming kidney myofibroblasts. Nat Med 2013; 19: 964-966
4. Perbal B. CCN proteins: Multifunctional signalling regulators. The Lancet 2004; 363: 62-64
5. Ivkovic S, Yoon BS, Popoff SN et al. Connective tissue growth factor coordinates chondrogenesis and angiogenesis during skeletal development. Development 2003; 130: 2779-2791
6. Baguma-Nibasheka M, Kablar B. Pulmonary hypoplasia in the connective tissue growth factor (CTGF) null mouse. Dev Dyn 2008; 237: 485-493
7. Mori Y, Hinchcliff M, Wu M et al. Connective tissue growth factor/ CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp Cell Res 2008; 314: 1094-1104
8. Bedore J, Sha W, McCann MR et al. Loss of notochord-derived CCN2 results in impaired intervertebral disc development and premature disc degeneration. Arthritis Rheum 2013. doi:10.1002/art.38075
9. Smerdel-Ramoya A, Zanotti S, Canalis E. Nephroblastoma overexpressed (Nov) induces gremlin in ST-2 stromal cell lines by post-transcriptional mechanisms. J Cell Biochem 2011; 112: 715-722
10. Smerdel-Ramoya A, Zanotti S, Stadmeyer L et al. Skeletal overexpression of connective tissue growth factor impairs bone formation and causes osteopenia. Endocrinology 2008; 149: 4374-4381
11. Lambi AG, Pankratz TL, Mundy C et al. The skeletal site-specific role of connective tissue growth factor in prenatal osteogenesis. Dev Dyn 2012; 241: 1944-1959
12. Okada H, Kikuta T, Kobayashi T et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol 2005; 16: 133-143
13. Wu S, Platteau A, Chen S et al. Conditional overexpression of connective tissue growth factor disrupts postnatal lung development. Am J Resp Cell Mol Biol 2010; 42: 552-563
14. Ito Y, Aten J, Bende RJ et al. Expression of connective tissue growth factor in human renal fibrosis. Kidney Int 1998; 53: 853-861
15. Murphy M, Godson C, Cannon S et al. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells. J Biol Chem 1999; 274: 5830-5834
16. Wang S, deNichilo M, Brubaker C et al. Connective tissue growth factor in tubulointerstitial injury of diabetic nephropathy. Kidney Int 2001; 60: 96-105
17. Shi-wen X, Leask A, Abraham D. Regulation and function of connective tissue growth factor/CCN2 in tissue repair, scarring and fibrosis. Cytokine and Growth Factor Reviews 2008; 19: 133-144
18. Kanemoto K, Usui J, Nitta K et al. In situ expression of connective tissue growth factor in human crescentic glomerulonephritis. Virchows Arch 2004; 444: 257-263
19. Cheng O, Thuillier R, Sampson E et al. Connective tissue growth factor is a biomarker and mediator of kidney allograft fibrosis. Am J Transplant 2006; 6: 2292-2306
20. Dendooven A, Gerritsen KG, Nguyen TQ et al. Connective tissue growth factor (CTGF/CCN2) ELISA: A novel tool for monitoring fibrosis. Biomarkers 2011; 16: 289-301
21. Tam FW, Riser BL, Meeran K et al. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine 2009; 47: 37-42
22. Metalidis C, van Vuuren SH, Broekhuizen R et al. Urinary connective tissue growth factor is associated with human renal allograft fibrogenesis. Transplantation 2013; 96: 494-500
23. Nguyen TQ, Tarnow L, Jorsal A et al. Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy. Diabetes Care 2008; 31: 1177-1182
24. Graness A, Poli V, Goppelt-Struebe M. STAT3-independent inhibition of lysophosphatidic acid-mediated upregulation of connective tissue growth factor (CTGF) by cucurbitacin I. Biochem Pharmacol 2006; 72: 32-41
25. Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 2012; 30: 49-59
26. Chaqour B, Goppelt-Struebe M. Mechanical regulation of the Cyr61/ CCN1 and CTGF/CCN2 proteins. FEBS J 2006; 273: 3639-3649
27. Yu X, Fang Y, Liu H et al. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration. Nephrol Dial Transplant 2012; 27: 3110-3119
28. Nguyen Q, Goldschmeding R. Bone morphogenetic protein-7 and connective tissue growth factor: Novel targets for treatment of renal fibrosis? Pharm Res 2008; 25: 2416-2426
29. Chen X-M, Qi W, Pollock CA. CTGF and chronic kidney fibrosis. Front Biosci (Schol Ed) 2009; 1: 132-141
30. Rayego Mateos S, Rodrigues-Diez R. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J Moll Cell Biol 2013; 5: 266-276
31. Rooney B, O'Donovan H, Gaffney A et al. CTGF/CCN2 activates canonical Wnt signalling in mesangial cells through LRP6: Implications for the pathogenesis of diabetic nephropathy. FEBS Lett 2011; 585: 531-538
32. Wahab NA, Weston BS, Mason RM. Connective tissue growth factor CCN2 interacts with and activates the tyrosine kinase receptor TrkA. J Am Soc Nephrol 2005; 16: 340-351
33. Kopp JB, Factor VM, Mozes M et al. Transgenic mice with increased plasma levels of TGF-beta 1 develop progressive renal disease. Lab Invest 1996; 74: 991-1003
34. Jos? G, Abreu NIKBR, De Robertis EM. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-β. Nat Cell Biol 2002; 4: 599-599
35. Chujo S, Shirasaki F, Kawara S et al. Connective tissue growth factor causes persistent proalpha2(I) collagen gene expression induced by transforming growth factor-beta in a mouse fibrosis model. J Cell Physiol 2005; 203: 447-456
36. Wang Q, Usinger W, Nichols B et al. Cooperative interaction of CTGF and TGF-b in animal models of fibrotic disease. Fibrogenesis Tissue Repair 2011; 4: 4
37. Kennedy L, Liu S, Shi-Wen X et al. CCN2 is necessary for the function of mouse embryonic fibroblasts. Experimental Cell Biol 2007; 313: 952-964
38. Shi-Wen X, Stanton L, Kennedy L et al. CCN2 is necessary for adhesive responses to transforming growth factor-?1 in embryonic fibroblasts. J Biol Chem 2006; 281: 10715-10726
39. Wahab NA, Weston BS, Mason RM. Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2. Exp Cell Res 2005; 307: 305-314
40. Lam S, van der Geest RN, Verhagen NAM et al. Connective tissue growth factor and IGF-I are produced by human renal fibroblasts and cooperate in the induction of collagen production by high glucose. Diabetes 2003; 52: 2975-2983
41. Mercurio S, Latinkic B, Itasaki N et al. Connective-tissue growth factor modulates WNT signalling and interacts with the WNT receptor complex. Development 2004; 131: 2137-2147
42. Nguyen TQ, Roestenberg P, van Nieuwenhoven FA et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J Am Soc Nephrol 2008; 19: 2098-2107
43. Nakerakanti SS, Bujor AM, Trojanowska M. CCN2 is required for the TGF-β induced activation of Smad1-Erk1/2 signaling network. PLoS ONE 2011; 6: E21911
44. Lian YG, Zhou QG, Zhang YJ et al. VEGF ameliorates tubulointerstitial fibrosis in unilateral ureteral obstruction mice via inhibition of epithelialmesenchymal transition. Acta Pharmacol Sin 2011; 32: 1513-1521
45. Inoki I, Shiomi T, Hashimoto G et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGFinduced angiogenesis. FASEB J 2002; 16: 219-221
46. Uchio K, Graham M, Dean NM et al. Down-regulation of connective tissue growth factor and type I collagen mRNA expression by connective tissue growth factor antisense oligonucleotide during experimental liver fibrosis. Wound Repair Regen 2004; 12: 60-66
47. Li G, Xie Q, Shi Y et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006; 8: 889-900
48. Wang X, Wu G, Gou L et al. A novel single-chain-Fv antibody against connective tissue growth factor attenuates bleomycin-induced pulmonary fibrosis in mice. Respirology 2011; 16: 500-507
49. Wang R, Xu Y-J, Liu X-S et al. Knockdown of connective tissue growth factor by plasmid-based short hairpin RNA prevented pulmonary vascular remodeling in cigarette smoke-exposed rats. Arch Biochem Biophys 2011; 508: 93-100
50. Liu S, Shi-wen X, Abraham DJ et al. CCN2 is required for bleomycininduced skin fibrosis in mice. Arthritis Rheum 2011; 63: 239-246
51. Sisco M, Kryger ZB, O'Shaughnessy KD et al. Antisense inhibition of connective tissue growth factor (CTGF/CCN2) mRNA limits hypertrophic scarring without affecting wound healing in vivo. Wound Repair Regen 2008; 16: 661-673
52. Yokoi H, Mukoyama M, Nagae T et al. Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J Am Soc Nephrol 2004; 15: 1430-1440
53. Luo GH, Lu YP, Song J et al. Inhibition of connective tissue growth factor by small interfering RNA prevents renal fibrosis in rats undergoing chronic allograft nephropathy. Transplant Proc 2008; 40: 2365-2369
54. Guha M, Xu Z-G, Tung D et al. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J 2007; 21: 3355-3368
55. Yokoi H, Mukoyama M, Mori K et al. Overexpression of connective tissue growth factor in podocytes worsens diabetic nephropathy in mice. Kidney Int 2008; 73: 446-455
56. Wang Q, Usinger W, Nichols B et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis and Tissue Repair 2011; 4: 4
57. Adler SG, Schwartz S, Williams ME et al. Phase 1 study of anti-CTGF monoclonal antibody in patients with diabetes and microalbuminuria. Clin J Am Soc Nephrol 2010; 5: 1420-1428
58. Morales MG, Gutierrez J, Cabello-Verrugio C et al. Reducing CTGF/ CCN2 slows down mdx muscle dystrophy and improves cell therapy. Hum Mol Genet 2013; doi: 10.1093/hmg/ddt352
59. Finger EC, Cheng CF, Williams TR et al. CTGF is a therapeutic target for metastatic melanoma. Oncogene 2013; doi: 10.1038/onc.2013.47
60. Neesse A, Frese KK, Bapiro TE. CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancer. Proc Natl Acad Sci USA 2013; 110: 12325-12330
61. Falke LL, Dendooven A, Leeuwis JW et al. Hemizygous deletion of CTGF/ CCN2 does not suffice to prevent fibrosis of the severely injured kidney. Matrix Biol 2012; 31: 421-431
62. Fragiadaki M, Witherden AS, Kaneko T et al. Interstitial fibrosis is associated with increased COL1A2 transcription in AA-injured renal tubular epithelial cells in vivo.Matrix Biol 2011; 30: 396-403
63. Lai C-F, Chen Y-M, Chiang W-C et al. Cysteine-rich protein 61 plays a proinflammatory role in obstructive kidney fibrosis. PLoS ONE 2013; 8: E56481
64. Riser BL, Najmabadi F, Perbal B et al. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 2009; 174: 1725-1734
65. Oemar BS, Lüscher TF. Connective tissue growth factor friend or foe? Arteriosclerosis. 1997; 17: 1483-1489
66. Leeuwis JW, Nguyen TQ, Theunissen MGJ et al. Connective tissue growth factor is associated with a stable atherosclerotic plaque phenotype and is involved in plaque stabilization after stroke. Stroke 2010; 41: 2979-2981
67. Dean RG, Balding LC, Candido R et al. Connective tissue growth factor and cardiac fibrosis after myocardial infarction. J Histochem Cytochem 2005; 53: 1245-1256
68. Panek AN, Posch MG, Alenina N et al. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS ONE 2009; 4: E6743
69. Gravning J, Ahmed MS, Lueder von TG et al. CCN2/CTGF attenuates myocardial hypertrophy and cardiac dysfunction upon chronic pressureoverload. Int J Cardiol 2013; 1-8
70. Moe IT, Pham TA, Hagelin E et al. CCN2 Exerts direct cytoprotective actions in adult cardiac myocytes by activation of the PI3-kinase/Akt/ GSK-3? signaling pathway. J Cell Commun Signal 2013; 7: 31-47
71. Capparelli C, Whitaker-Menezes D, Guido C et al. CTGF drives autophagy, glycolysis and senescence in cancer-Associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 2012; 11: 2272-2284
72. Haase VH. Oxygen regulates epithelial-to-mesenchymal transition: Insights into molecular mechanisms and relevance to disease. Kidney Int 2009; 76: 492-499
73. Gerritsen KG, Abrahams AC, Peters HP et al. Effect of GFR on plasma Nterminal connective tissue growth factor (CTGF) concentrations. Am J Kidney Dis 2012; 59: 619-627